| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/11/2003 | US20030171320 Methods for treating ocular neovascular diseases |
| 09/11/2003 | US20030171317 Methods and compositions for reducing bacterial tolerance to antibacterials, disinfectants and organic solvents |
| 09/11/2003 | US20030171314 Early protection of susceptible animals against foot and mouth disease (FMD) may be achieved by inoculating the animals with a vaccine comprising an interferon DNA sequence. One day after inoculation, animals have been found protected from |
| 09/11/2003 | US20030171290 Methods to determine peptides presented on the surface of mammalian cells following addition to the cells of a protein. The present invention also relates to diagnostic tests based on the determination of such peptides or modified molecules |
| 09/11/2003 | US20030171283 Inhibin compositions and methods of enhancing production performance |
| 09/11/2003 | US20030171267 Albumin fusion proteins |
| 09/11/2003 | US20030171266 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 09/11/2003 | US20030171261 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer |
| 09/11/2003 | US20030171254 Purified outer membrane protein of a Moraxella strain, particularly M. catarrhalis, having a molecular mass of about 200 kDa, is provided. The about 200 kDa outer membrane protein as well as nucleic acid molecules encoding the same are useful |
| 09/11/2003 | US20030170898 Method for intracellular modifications within living cells using pulsed electric fields |
| 09/11/2003 | US20030170856 Regulation of human map kinase phosphatase-like enzyme |
| 09/11/2003 | US20030170843 Carbohydrate crosslinked glycoprotein crystals |
| 09/11/2003 | US20030170839 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/11/2003 | US20030170838 Novel polynucleotides and polypeptides encoded thereby |
| 09/11/2003 | US20030170823 Polynucleotide encoding a polypeptide; induces proliferation or cytotoxicity in cells; use in increasing platelets and in detection of cancer, inflammation and genetic abnormalities |
| 09/11/2003 | US20030170792 MAGE-3 peptides presented by HLA class ll molecules |
| 09/11/2003 | US20030170784 Secreted proteins and uses thereof |
| 09/11/2003 | US20030170782 Proteins |
| 09/11/2003 | US20030170763 Protein antiallergens |
| 09/11/2003 | US20030170761 Neutralizing epitopes; induce immunology response |
| 09/11/2003 | US20030170756 Treatment of tumor cells for use in immunotherapy of cancer |
| 09/11/2003 | US20030170750 Urogenital carcinoma tlp complex peptides and antibodies thereof |
| 09/11/2003 | US20030170719 Antiinflammatory agents; autoimmune disease; anticancer agents |
| 09/11/2003 | US20030170718 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/11/2003 | US20030170707 Cancer diagnosis; prevent gene expression in sample; induce immunology response |
| 09/11/2003 | US20030170658 Genetic engineered retroviruses; detecting antigen, antibody complex; medical diagnosis |
| 09/11/2003 | US20030170657 Protein; inducting antibodies; gene expression; diagnosis, vaccines |
| 09/11/2003 | US20030170620 Gene controlling androgen |
| 09/11/2003 | US20030170618 Buffers for stabilizing antigens |
| 09/11/2003 | US20030170616 Diagnosis using antibodies; genetic engineering |
| 09/11/2003 | US20030170614 Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| 09/11/2003 | US20030170277 Generating immunogenic oocysts for a vaccine against Coccidiosis. |
| 09/11/2003 | US20030170276 Modified msbB gene |
| 09/11/2003 | US20030170274 Activation of HCV-specific T cells |
| 09/11/2003 | US20030170273 Type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules for enhancing the immune response of a coadministered antigen |
| 09/11/2003 | US20030170272 EIA vaccine and diagnostic |
| 09/11/2003 | US20030170271 Chimeric papillomavirus-like particles |
| 09/11/2003 | US20030170270 Nucleic acid encoding an infectious, nonpathogenic PCV1, which contains an immunogenic open reading frame gene of a pathogenic PCV2 in place of an ORF gene of the PCV1 nucleic acid molecule. |
| 09/11/2003 | US20030170269 Vaccine for mystery swine disease and method for diagnosis thereof |
| 09/11/2003 | US20030170268 Administering a fusion protein of a heat shock protein or immunostimulatory fragment and a human papilloma virus protein or an antigenic fragment; or a nucleic acid coding the fusion protein |
| 09/11/2003 | US20030170267 Conjugate vaccines |
| 09/11/2003 | US20030170264 Stabilisation of plasmid inheritance in bacteria |
| 09/11/2003 | US20030170263 Expression system |
| 09/11/2003 | US20030170262 Immunogenic detoxified mutant E. coli LT-A toxin |
| 09/11/2003 | US20030170261 From Neisseria meningitidis; attenuated microorganismsthat have a reduced ability to take up DNA; vaccines |
| 09/11/2003 | US20030170260 Binds antibodies specific for Rhodococcus equi and the VapA protein. |
| 09/11/2003 | US20030170259 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/11/2003 | US20030170258 Transmucosally administering an epitope which is located in close proximity to said immune response, wherein said modulation comprises induction of oral tolerization to said antigen. |
| 09/11/2003 | US20030170257 Protecting animals against the bite of blood-sucking ectoparasites and against the transmission of viruses, bacteria and other pathogens by such ectoparasites. |
| 09/11/2003 | US20030170253 Useful in stimulating angiogenesis as well as in diagnostic applications. |
| 09/11/2003 | US20030170252 Also a hybridoma cell capable of producing the antibody; anticancer agents |
| 09/11/2003 | US20030170251 Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
| 09/11/2003 | US20030170249 Vaccines directed to cancer-associated carbohydrate antigens |
| 09/11/2003 | US20030170248 Constant region contains a human immunoglobulin and variable region contains a non-human immunoglobulin variable region; especially treating an infection caused by Enterohemorrhagic Escherichia coli |
| 09/11/2003 | US20030170247 Methods for detection and treatment of neural cancers |
| 09/11/2003 | US20030170246 Fusion protein, comprising a first lipophilin-like polypeptide linked by a peptide bond to a second lipophilin-like polypeptide; polynucleotides encoding the protein; antibodies; especially for breast, ovarian or prostate cancer. |
| 09/11/2003 | US20030170243 Use of human plasma hyaluronidase in cancer treatment |
| 09/11/2003 | US20030170242 Novel isoforms of vascular endothelial cell growth inhibitor |
| 09/11/2003 | US20030170238 Increasing the cytokine production of T-cells; preferably the cells are allowed to rest after harvest and then are re-activated just prior to infusion. |
| 09/11/2003 | US20030170235 Treatment with anti-ErbB2 antibodies |
| 09/11/2003 | US20030170234 Combination of the antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin; treating cancer |
| 09/11/2003 | US20030170233 Treating Autoimmune Diseases with Humanized Anti-CD40L Antibody |
| 09/11/2003 | US20030170228 Compositions and methods for the treatment of tumor |
| 09/11/2003 | US20030170212 Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 09/11/2003 | US20030170211 For delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to be expressed in the animal or the animal cells |
| 09/11/2003 | US20030170175 Cytotoxic therapy |
| 09/10/2003 | EP1342727A1 Antibody against norwalk virus and method of detecting virus by using the antibody |
| 09/10/2003 | EP1342476A2 FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours |
| 09/10/2003 | EP1342469A2 Stable glass state powder formulations |
| 09/10/2003 | EP1341923A2 Methods for enhancing the efficacy of cancer therapy |
| 09/10/2003 | EP1341915A1 Use of cells derived from embryonic stem cells for increasing transplantation tolerance and for repairing damaged tissue |
| 09/10/2003 | EP1341819A2 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
| 09/10/2003 | EP1341810A2 Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type iii secretion pathway of a gram-negative bacteria. |
| 09/10/2003 | EP1341782A2 Inhibitors of p38 kinase |
| 09/10/2003 | EP1341553A1 Silensed anti-cd28 antibodies and use thereof |
| 09/10/2003 | EP1341552A2 Treatment of immune-mediated diseases by oral administration of plasma fractions |
| 09/10/2003 | EP1341551A2 Treatment of posterior capsule opacification |
| 09/10/2003 | EP1341546A2 Kyberdrug as autovaccines with immune-regulating effects |
| 09/10/2003 | EP1169044B1 Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence |
| 09/10/2003 | EP1054689B1 Strategically modified hepatitis b core proteins and their derivatives |
| 09/10/2003 | EP1047449B1 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration |
| 09/10/2003 | EP0948342B1 MEDICAL USES OF scuPA/suPAR COMPLEX |
| 09/10/2003 | EP0873139B1 Biotinylated antibodies with reduced net positive charge and toxin, drug or chelate |
| 09/10/2003 | EP0783299B1 Compounds and compositions for delivering active agents |
| 09/10/2003 | EP0594732B1 Humanized antibody against cd18 |
| 09/10/2003 | CN1441842A Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof |
| 09/10/2003 | CN1441811A Anti-body capable to selectively detect prion PrPsc isoforms |
| 09/10/2003 | CN1441807A Hepatitis B core antigen fusion proteins |
| 09/10/2003 | CN1441677A Combined use of anti-cytokine antibodies or antagonists and anti-CD2O for treatment of B cell lymphoma |
| 09/10/2003 | CN1441676A Method of treatment using ligand-immunogen conjugates |
| 09/10/2003 | CN1441675A Compositions and methods for achieving immune suppression |
| 09/10/2003 | CN1441670A Highly efficient delivery of large therapeutic mass aerosol |
| 09/10/2003 | CN1440816A Improvement for diagnosis and/or therapeutic agnet and its relative improvement |
| 09/10/2003 | CN1440812A Method of strengthening immune response with CD137 conjugated excitomotor |
| 09/10/2003 | CN1440811A Contraception vaccine cross-linked with molecular adjuvant |
| 09/10/2003 | CN1440810A Prepn of clostridium welchil toxoid vaccine and antitoxin serum |
| 09/09/2003 | US6617441 Nucleic acid segment encoding a polypeptide of given amino acid sequence; lyme disease; flagellin and rRNA genes |
| 09/09/2003 | US6617349 Blends of isoflavones and flavones |
| 09/09/2003 | US6617312 Contains a sequence motif selected from the group consisting of the motifs (Asp or Glu)-Ala-Trp-(Lys or Arg) or (Tyr or Cys)-(Glu or Asp)-(Leu or Ile)-Trp; binds to vasoactive amines such as histamine |
| 09/09/2003 | US6617157 Using inactivating agent of given formula to inactivate any virus contained in donor blood, blood products, or other biological compositions; can also use in vaccines |